
Opinion|Videos|June 9, 2025
Education and Support After Progression ALK Inhibitors
Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing on lorlatinib.
Advertisement
Episodes in this series

Patient Education and Transition Between Therapies
Key Themes:
- Approaches to patient education after disease progression
- Real-world challenges during therapy transitions
- Current options for patients progressing on lorlatinib
Notable Insights:
- Castronovo outlined approaches to patient education when discussing next steps after progression
- Grizzard identified real-world challenges patients face when transitioning between therapies
- Dr Dietrich presented current best options for patients progressing on lorlatinib
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AI Chatbots Score Below 28% on Colorectal Cancer Questions
2
5 Notable FDA Approvals From the First Half of 2026
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
5





